$VKTX

U.S. stocks fell as Iranian drone strike on UAE port sent crude above $114/barrel, triggering inflation concerns and potential Fed rate hike expectations by March 2027.

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.

Pfizer's 6.55% dividend yield offers attractive income but reflects patent cliff and pandemic revenue decline pressures. Strategic restructuring and Seagen acquisition signal transformation bid.

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.

$VKING develops competing obesity drugs against $LLY and $NVO, with oral candidate entering phase 3 trials in Q3 2026 amid projected $100B market expansion.

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.

Viking Therapeutics' VK2735 targets the $100+ billion weight-loss market. Success could drive massive stock appreciation, but clinical and competitive risks remain substantial.

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.

Viking Therapeutics finishes enrolling 1,000 patients in Phase 3 VANQUISH-2 trial of VK2735 for obesity treatment, with results expected in 2027.

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.

Global health market reaches $6 trillion milestone by 2026, driven by consumer demand for wellness products. Companies expand through innovation in digital health, pharmaceuticals, and specialized care solutions.